Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0373 |
Erlotinib
OSI-744,NSC 718781,CP358774,埃罗替尼,R1415 |
EGFR; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Erlotinib (NSC-718781) 是一种直接作用的EGFR 酪氨酸激酶抑制剂,用于治疗非小细胞肺癌,对人 EGFR 的IC50为 2 nM。它可降低完整肿瘤细胞的 EGFR 自磷酸化,IC50为 20 nM。 | |||
T6328 |
Desmethyl Erlotinib
OSI-420,CP-473420,O-Desmethyl Erlotinib |
EGFR; Drug Metabolite | Angiogenesis; JAK/STAT signaling; Metabolism; Tyrosine Kinase/Adaptors |
Desmethyl Erlotinib (CP-473420) 是 Erlotinib 的活性代谢物。Erlotinib 是 EGFR 酪氨酸激酶抑制剂。 | |||
T6619 |
Desmethyl Erlotinib hydrochloride
OSI420,OSI-420,DesMethyl Erlotinib (CP-473420) HCl,去甲厄洛替尼,CP-473420,Desmethyl Erlotinib,OSI 420 |
EGFR; Drug Metabolite | Angiogenesis; JAK/STAT signaling; Metabolism; Tyrosine Kinase/Adaptors |
Desmethyl Erlotinib hydrochloride (OSI 420) 是 Erlotinib 的活性代谢物。Erlotinib 是 EGFR 酪氨酸激酶抑制剂。 | |||
T0373L |
Erlotinib hydrochloride
盐酸埃罗替尼,OSI-744,NSC 718781,Erlotinib HCl,CP-358774 |
EGFR; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Erlotinib hydrochloride (NSC 718781) 抑制EGFR 激酶的IC50为 2 nM,用于治疗非小细胞肺癌。 | |||
T35915 |
Erlotinib-13C6
Erlotinib-13C6 |
||
Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]... | |||
T19312 |
Erlotinib-d6 hydrochloride
CP-358774 D6 hydrochloride,NSC 718781 D6 hydrochloride,Erlotinib D6 hydrochloride,OSI-774 D6 hydrochloride |
Others | Others |
Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib D6 hydrochloride a deuterium labeled Erlotinib Hydrochloride. | |||
T11229 |
Erlotinib-d6
OSI-774 D6,NSC 718781 D6,CP-358774 D6 |
Others | Others |
Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib . | |||
T0373L1 |
Erlotinib mesylate
CP-358774,CP-358,774,埃罗替尼甲磺酸盐,OSI-774,CP358774,OSI 774 |
||
Erlotinib is an epidermal growth factor receptor inhibitor. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. | |||
T31055 |
CP-457493
OSI-493,Erlotinib metabolite M6,CP457493,UNII-X0JH558S7E |
||
CP-457493 is a bio-active chemical. | |||
T35528 |
TD52
|
Apoptosis; Phosphatase; Akt | Apoptosis; Cytoskeletal Signaling; Metabolism; PI3K/Akt/mTOR signaling |
TD52 是 PP2A (CIP2A) 癌性抑制剂的口服活性抑制剂。 TD52 是厄洛替尼衍生物,通过干扰 Elk1 与 CIP2A 启动子的结合间接降低了 CIP2A。 | |||
T35528L |
TD52 dihydrochloride
TD52 dihydrochloride(1798328-24-1 Free base),TD52 2HCl |
Others | Others |
TD52 dihydrochloride (TD52 2HCl), a derivative of Erlotinib, is a potent and orally active inhibitor of protein phosphatase 2A (CIP2A). It exhibits strong anti-cancer properties by regulating the CIP2A/PP2A/p-Akt signaling pathway, resulting in the induction of apoptosis in triple-negative breast cancer (TNBC) cells. Mechanistically, TD52 dihydrochloride disrupts the binding of Elk1 to the CIP2A promoter, effectively reducing CIP2A levels. Notably, TD52 dihydrochloride demonstrates powerful anti... | |||
T22343 |
HKB99
|
Others | Others |
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, could suppresse tumor growth and metastasis and overcome erlotinib resistance in non-small-cell lung cancer (NSCLC) | |||
T34892 |
TM608
TM-608,TM 608 |
||
TM608 is a potent selective c-Met inhibitor that targets mitochondria and kills erlotinib-resistant lung cancer cells, rapidly accumulates in mitochondria, and inhibits MET activation in high MET expression, erlotinib-resistant HCC827B cells (total cell l | |||
T35147 |
WZ4002-hydroxy
WZ4002 analog, WZ4002 demethyl derivate,WZ 4002-hydroxy,WZ-4002-hydroxy |
||
WZ4002-hydroxyl is a WZ4002 derivative or WZ4002 analogue in which methoxy is replaced by hydroxyl and can be detected in 50% of patients with clinical resistance to gefitinib or erlotinib. WZ4002 has a basic chemical skeleton (covalent pyrimidine) that d | |||
T71526 | CH5164840 | ||
CH5164840 is a potent and selective HSP90 inhibitor. CH5164840 showed remarkable antitumor activity against NSCLC cell lines and xenograft models. CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations. | |||
T69888 |
SB02024
|
||
SB02024 is a VPS34 inhibitor. SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity... | |||
T73472 | Erasin | ||
Erasin 是一种有效的 Erlotinib 抗性STAT3抑制剂,对STAT3和STAT1的IC50分别为 9.7 和 24 μM。Erasin 诱导癌细胞凋亡(apoptosis)。 | |||
T36102 |
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
|
||
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.1,2,3,4,5It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.1,2,3It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib , with antiproliferative activity.4,5 |